AMPEL BioSolutions recently announced a breakthrough treatment method that could change how healthcare professionals treat patients who are suffering from autoimmune and infectious diseases, as well as cancer. This technology has the ability to completely transform the way healthcare professionals treat their patients, and in turn, has the potential to improve the quality of life for patients suffering from diseases, says GlobalData, a leading data and analytics company.
The technology will use RNA analytics and machine learning to characterize the patient’s genes and provide clinical decision support to the healthcare professional. AMPEL intends for its technology to detect early signs of disease and then group patients by the severity of their condition, so their treatment is more precise.
Alexandra Murdoch, Medical Analyst at GlobalData, comments: “Having the ability to really treat the patient as opposed to the disease is important. While understanding the disease is necessary, every patient is different, and it’s time that their treatment options reflect that. This technology will help physicians do that, and as a result patient care will improve tremendously.”
Currently, the technology is assisting more than 15 pharmaceutical companies in drug development and clinical trials. AMPEL expects to bring two products to the market over the next few years: LuGENE, which is a blood test for Lupus, and DermaGENE, a skin biopsy test for Psoriasis, Atopic Dermatitis, Scleroderma, and Lupus.
As well as its new technology, AMPEL also has a pipeline of big data tools which are used to analyze large and complex clinical datasets. These products together will be a significant step forward for implementing routine testing to monitor disease activity and provide decision support.Murdoch concludes: “Big data and genomics are important for the future of healthcare. These tools provide healthcare professionals with a plethora of more information than if they look solely at the disease. Access to gene expression and clinical datasets will provide a closer look at the individual as well as the disease. This type of care will become more common in the future, and AMPEL BioSolutions is headed in the right direction.”
